Tim Story, a Mississippi football coach, was given months to live after late-stage colon cancer. He enrolled in a clinical ...

New research shows that fecal transplants may boost the effectiveness of cancer immunotherapy drugs called PD-1 inhibitors.

This €1.6 Million financing will allow MSInsight to finalize MSIcare's technological development, demonstrate its performance ...

Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. Currently, all ...

Elevated expression of DHX9 has been reported in multiple cancer types and it is associated with poor prognosis. In a recently published study, researchers from Accent Therapeutics Inc. evaluated ...

Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. I will now turn the call ...

combo as a first-line treatment for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (mCRC). The potential treatment is ...

Operator: Good morning and welcome to Agenus Inc.’s Fourth Quarter and Year-End 2024 Earnings Conference Call. Currently all ...

A humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results ...

Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...